This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-αvβ integrin receptor IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the αvβ integrin receptor as well as the biological activity of IL2. The antibody can enhance the activity of cytotoxic drug based therapies, leading to more anti-tumor activity in vivo. The antibody causes the depolymerization of focal adhesions dependent on αvβ3 and αvB5. These signalling complexes assemble after integrin ligation. They organize communication with growth, survival and motility pathways, and their destruction can trigger apoptosis. Thus antibody uses a combination of mechanochemical and biochemical effects to affect endothelia and to increase stress on tumor cells. This immunocytokine was designed for treating tumor.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-076 | Anti-Human CD51 Recombinant Antibody (TAB-076) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG1 - kappa |
There are currently no Customer reviews or questions for ACFP-SH136. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.